Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes

Akira Yoshida,1,2*, Kouichi Zokumasu,1 Yuji Wano,3 Takahiro Yamauchi,1 Shin Imamura,4 Kazutaka Takagi,1 Shinji Kishi,1 Yoshimasa Urasaki,1 Kaoru Tohyama,5 and Takanori Ueda1

1Department of Hematology and Oncology, Faculty of Medicine; 2Translational Research Center, University of Fukui, Matsuoka, Elheiji-Chou, Fukui; 3Department of Hematology, Iwate Prefectural Hospital, Morioka; 4Department of Hematology, Fukui Red Cross Hospital, Fukui; and 5Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan


Online Supplementary Figure S1. Representative dot plot of flow cytometry for CD34 expression in the sample after magnetic separation. BM sample was obtained from a patient with MDS (RA). CD34+ cells were enriched using Mac beads column as described in the Design and Methods section.
Online Supplementary Figure S2. Comparison of Survivin and Aurora-B kinase expression in each patient with MDS, s-AML and de novo AML (d-AML). Red and green bar indicates Survivin and Aurora-B kinase expression, respectively. Survivin or Aurora-B kinase expression was evaluated by RQ-PCR as described in Design and Methods section. d-AML: de novo AML.